Pressure BioSciences, Inc.
PBIO · OTC
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Revenue | $1,978 | $1,729 | $2,002 | $1,221 |
| % Growth | 14.4% | -13.6% | 64% | – |
| Cost of Goods Sold | $1,178 | $2,014 | $942 | $583 |
| Gross Profit | $800 | -$285 | $1,060 | $638 |
| % Margin | 40.4% | -16.5% | 52.9% | 52.2% |
| R&D Expenses | $1,367 | $970 | $1,102 | $1,143 |
| G&A Expenses | $8,205 | $3,243 | $3,819 | $3,430 |
| SG&A Expenses | $8,936 | $3,644 | $4,144 | $4,080 |
| Sales & Mktg Exp. | $731 | $401 | $325 | $650 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $10,303 | $4,614 | $5,245 | $5,224 |
| Operating Income | -$9,503 | -$4,898 | -$4,185 | -$4,586 |
| % Margin | -480.5% | -283.2% | -209% | -375.7% |
| Other Income/Exp. Net | -$19,811 | -$11,178 | -$15,968 | -$11,420 |
| Pre-Tax Income | -$29,314 | -$16,077 | -$20,153 | -$16,006 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$29,314 | -$16,077 | -$20,153 | -$16,006 |
| % Margin | -1,482.2% | -929.6% | -1,006.5% | -1,311.3% |
| EPS | -1.51 | -1.61 | -3.42 | -5.32 |
| % Growth | 6.2% | 52.9% | 35.7% | – |
| EPS Diluted | -1.51 | -1.61 | -3.42 | -5.32 |
| Weighted Avg Shares Out | 23,337 | 11,058 | 6,637 | 3,304 |
| Weighted Avg Shares Out Dil | 23,337 | 11,058 | 6,637 | 3,304 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $15,581 | $10,439 | $14,450 | $8,344 |
| Depreciation & Amortization | $112 | $233 | $175 | $204 |
| EBITDA | -$9,391 | -$5,405 | -$5,528 | -$7,457 |
| % Margin | -474.8% | -312.5% | -276.1% | -611% |